Biomerica Inc. (BMRA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Biomerica Inc. (BMRA:NASDAQ), powered by AI.

Current Price
$2.17
P/E Ratio
-1.0
Market Cap
5M
Sector
Healthcare
What is the Biomerica Inc. stock price forecast?

Biomerica Inc. is currently trading at $2.17. View real-time AI analysis on Alpha Lenz.

What is Biomerica Inc. insider trading activity?

View the latest insider trading data for Biomerica Inc. on Alpha Lenz.

What is Biomerica Inc.'s P/E ratio?

Biomerica Inc.'s P/E ratio is -1.0.

Biomerica Inc.

$2.17
NASDAQBMRA
Ask about Biomerica Inc.'s future dividend policy...
Alpha Chat Insight

Biomerica Inc. trades at a P/E of -1.0 (undervalued) with modest ROE of -93.0%.

Ask for details

Company Overview

Biomerica Inc. operates within the healthcare sector as a developer and manufacturer of advanced medical diagnostic products. The primary function of Biomerica Inc. is to innovate in the realm of diagnostic testing, with a focus on chronic diseases and conditions. Their portfolio includes products designed for the early detection and management of illnesses such as diabetes, gastrointestinal disorders, and various forms of cancer. Through its cutting-edge technology, Biomerica Inc. aims to improve patient care by offering precise and reliable testing solutions that can be utilized in clinical laboratories, hospitals, and research institutions. Biomerica's work significantly impacts the healthcare industry by catering to the rising demand for efficient diagnostic tools that help in timely disease intervention. Based in Irvine, California, and with a global presence, Biomerica Inc. positions itself as a pivotal player in enhancing healthcare delivery and contributing to clinical advancements by providing products that drive better health outcomes.

CEOMr. Zackary S. Irani
SectorHealthcare
IndustryMedical Devices
Employees53

Company Statistics

(FY 2025)

Profile

Market Cap$4.98M
Revenue$5.31M
Shares Out0.00
Employees53

Margins

Gross9.38%
EBITDA-89.19%
Operating-96.72%
Pre-Tax-93.62%
Net-93.64%

Valuation

P/E-1.00
P/B1.21
EV/Sales0.94
EV/EBITDA-0.64
P/FCF-1.29

Growth (CAGR)

Rev 3Yr-34.47%
Rev 5Yr-4.52%
Op Inc 3YrN/A
Op Inc 5YrN/A
Net Inc 3YrN/A
Net Inc 5YrN/A

Returns

ROA-65.44%
ROE-92.99%
ROIC-67.60%

Financial Health

Cash & Cash Equivalents$2.40M
Net Debt$-559.00K
Debt/Equity44.82%
Interest CovN/A
Ask Alpha Chat

Frequently Asked Questions

Alpha Lenz
Singapore
CEO: Kyungtae Kim | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2025 Treasurer. All rights reserved.
Biomerica Inc. (Healthcare) Stock Forecast & Analysis $2.17 | Alpha Lenz